Markus D. Lacher

506 total citations
26 papers, 412 citations indexed

About

Markus D. Lacher is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Markus D. Lacher has authored 26 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Genetics. Recurrent topics in Markus D. Lacher's work include CAR-T cell therapy research (7 papers), Acute Myeloid Leukemia Research (6 papers) and Virus-based gene therapy research (5 papers). Markus D. Lacher is often cited by papers focused on CAR-T cell therapy research (7 papers), Acute Myeloid Leukemia Research (6 papers) and Virus-based gene therapy research (5 papers). Markus D. Lacher collaborates with scholars based in United States, Switzerland and Australia. Markus D. Lacher's co-authors include W. Michael Korn, Christine Christian, Robert R. Friis, Arun Dharmarajan, Robert S. Warren, Maarit Tiirikainen, Susanne Saurer, Roxana Pincheira, Ariel F. Castro and Marisa Shiina and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Markus D. Lacher

24 papers receiving 402 citations

Peers

Countries citing papers authored by Markus D. Lacher

Since Specialization

Citations

This map shows the geographic impact of Markus D. Lacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus D. Lacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus D. Lacher more than expected).

Fields of papers citing papers by Markus D. Lacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus D. Lacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus D. Lacher. The network helps show where Markus D. Lacher may publish in the future.

Co-authorship network of co-authors of Markus D. Lacher

This figure shows the co-authorship network connecting the top 25 collaborators of Markus D. Lacher. A scholar is included among the top collaborators of Markus D. Lacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus D. Lacher. Markus D. Lacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	AML-117: A Phase 1b Study of Selinexor and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Somedeb Ball, Michael Byrne, Melissa A. Fischer, Farrukh T. Awan, Benjamin Tomlinson, (unknown), (unknown), Christine Gu, Christopher Leonardi, Katherine Walsh, Gregory D. Ayers, Ashwin Kishtagari, (unknown), Markus D. Lacher, Joseph Wagner, Sanjay Mohan, Michael R. Savona	0
2	AML-553 Revival of the PLK1 Inhibitor Volasertib in Relapsed/Refractory Acute Myeloid Leukemia 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Glenn Michelson, (unknown), Christopher Leonardi, Christine Gu, Markus D. Lacher, Joseph Wagner	1
3	Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia 2024 ·Blood ·Somedeb Ball, Michael Byrne, Melissa A. Fischer, Farrukh T. Awan, (unknown), (unknown), (unknown), Christine Gu, Christopher Leonardi, Katherine Walsh, Gregory D. Ayers, Ashwin Kishtagari, (unknown), Markus D. Lacher, Joseph Wagner, Sanjay Mohan, Michael R. Savona	1
4	Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay 2023 ·JCO Precision Oncology ·Elliot Stieglitz, Christine Gu, Michelle Richardson, (unknown), (unknown), (unknown), Debbie Strachan, (unknown), George Yam, Wade Anderson, Erica Anderson, (unknown), Sarah K. Tasian, Mignon L. Loh, Markus D. Lacher	1
5	Regression of Breast Cancer Metastases Following Treatment withIrradiated SV-BR-1-GM, a GM-CSF Overexpressing Breast Cancer CellLine: Intellectual Property and Immune Markers of Response 2022 ·Recent Patents on Anti-Cancer Drug Discovery ·Charles L. Wiseman, (unknown), Vivekananda Gupta Sunkari, (unknown), (unknown), (unknown), (unknown), William V. Williams, Markus D. Lacher	7
6	Hyper engorged cancer associated macrophage-like cells in circulation predict for multi-organ metastatic disease in solid tumors. 2021 ·Journal of Clinical Oncology ·(unknown), Raymond C. Bergan, Steven H. Lin, R. Katherine Alpaugh, Massimo Cristofanilli, Saranya Chumsri, Rena G. Lapidus, William L. Williams, Markus D. Lacher, Daniel C. Danila, (unknown), Thai H. Ho, Martin J. Edelman, Cha‐Mei Tang, Daniel L. Adams	1
7	Development of a multiomics and functional drug sensitivity platform to investigate cell type specific drug effects in AML. 2021 ·Journal of Clinical Oncology ·(unknown), Ryosuke Kita, Steven Schaffert, Erica Anderson, (unknown), Debbie Strachan, Markus D. Lacher, Wade Anderson, (unknown), (unknown), (unknown), (unknown), (unknown), Laura Henry, (unknown), (unknown), (unknown), Joseph Wagner	0
8	SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4+ T Lymphocytes 2018 ·Frontiers in Immunology ·Markus D. Lacher, Gerhard Bauer, Brian Fury, (unknown), (unknown), (unknown), (unknown), (unknown), Nicholas H. Perotti, Ying Kong, William W. Kwok, (unknown), Charles L. Wiseman, William V. Williams	19
9	Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors 2013 ·Recent Patents on Anti-Cancer Drug Discovery ·Markus D. Lacher, Maurizio Provenzano	1
10	ZEB1 limits adenoviral infectability by transcriptionally repressing the Coxsackie virus and Adenovirus Receptor 2011 ·Molecular Cancer ·Markus D. Lacher, Marisa Shiina, Peter Chang, Debora Keller, Maarit Tiirikainen, W. Michael Korn	22
11	Evaluating the genomic and sequence integrity of human ES cell lines; comparison to normal genomes 2011 ·Stem Cell Research ·Walter D. Funk, Ivan Labat, (unknown), Pierre‐Antoine Gourraud, Jorge R. Oksenberg, Elen Rosler, (unknown), (unknown), Stacy J. Caillier, (unknown), Julie A. Johnson, Lorraine F. Meisner, Markus D. Lacher, Karen Chapman, Myung Jin Park, Kyoung‐Jin Shin, (unknown), Michael D. West	22
12	Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer 2011 ·Small GTPases ·Markus D. Lacher, Roxana Pincheira, Ariel F. Castro	13
13	Spontaneous Reversal of the Developmental Aging of Normal Human Cells Following Transcriptional Reprogramming 2010 ·Regenerative Medicine ·Homayoun Vaziri, (unknown), (unknown), Jonathan H. Teichroeb, Markus D. Lacher, Hal Sternberg, Ilyas Singeç, Laura Briggs, (unknown), (unknown), Rodolfo Gonzalez, David LaRocca, James T. Murai, E.Y. Snyder, W. H. Horner Andrews, (unknown), Michael D. West	51
14	Rheb activates AMPK and reduces p27Kip1 levels in Tsc2-null cells via mTORC1-independent mechanisms: implications for cell proliferation and tumorigenesis 2010 ·Oncogene ·Markus D. Lacher, Roxana Pincheira, Zhou Zhu, Blanca Camoretti-Mercado, Mary Matli, Robert S. Warren, Ariel F. Castro	35
15	RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses 2009 ·Cancer Gene Therapy ·Marisa Shiina, Markus D. Lacher, Christine Christian, W. Michael Korn	20
16	SFRP-4 abrogates Wnt-3a-induced β-catenin and Akt/PKB signalling and reverses a Wnt-3a-imposed inhibition of <em>in vitro</em> mammary differentiation 2008 ·PubMed ·(unknown), (unknown), Markus D. Lacher, Susanne Saurer, Robert R. Friis, Arun Dharmarajan	33
17	Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation 2006 ·Cancer Gene Therapy ·W. Michael Korn, Mónica Macal, Christine Christian, Markus D. Lacher, A McMillan, Katherine A. Rauen, Robert S. Warren, Linda D. Ferrell	52
18	Transforming Growth Factor-β Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition 2006 ·Cancer Research ·Markus D. Lacher, Maarit Tiirikainen, Elise F. Saunier, Christine Christian, Mario Anders, Martin Oft, Allan Balmain, Rosemary J. Akhurst, W. Michael Korn	60
19	Role of DDC-4/sFRP-4, a secreted Frizzled-related protein, at the onset of apoptosis in mammary involution 2003 ·Cell Death and Differentiation ·Markus D. Lacher, (unknown), Richard Jäger, Yan Xi, (unknown), Li‐Jiang Xuan, Susanne Saurer, Ricky R. Lareu, Arun Dharmarajan, Robert R. Friis	44
20	Regulated Expression of Inhibitor of Apoptosis Protein 3 in the Rat Corpus Luteum1 2003 ·Biology of Reproduction ·Ricky R. Lareu, Markus D. Lacher, Cara K. Bradley, R. Sridaran, Robert R. Friis, Arun Dharmarajan	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact